Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Feb 21;11:393–401. doi: 10.2147/OPTH.S128509

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 Blinder et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Response rates after each anti-VEGF injection.

Notes: (A) Percentage of patients with 20/40 or better BCVA. The number of patients for injection numbers 0 through 12 was 130, 133, 135, 129, 113, 101, 79, 53, 45, 39, 23, 14, and 13, respectively. (B) Percentage of patients with CRT ≤250 μm on TD-OCT or ≤300 μm on SD-OCT. The number of patients for injection numbers 0 through 12 was 119, 118, 122, 129, 106, 83, 80, 61, 47, 43, 25, 23, and 17, respectively.

Abbreviations: BCVA, best-corrected visual acuity; CRT, central retinal thickness; SD-OCT, spectral-domain optical coherence tomography; TD-OCT, time-domain optical coherence tomography; VEGF, vascular endothelial growth factor.